We are live on ! Find out more
DMAQR

Deep Medicine Acquisition Corp. Rights
DMAQR

Delisted

DMAQR was delisted on the 31st of January, 2024.

33 hedge funds and large institutions have $3.2M invested in Deep Medicine Acquisition Corp. Rights in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
33
Holders Change
+33
Holders Change %
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
33
Increased
Reduced
Closed
Calls
$336K
Puts
Net Calls
+$336K
Net Calls Change
+$336K
Name Holding Trade Value Shares
Change
Change in
Stake
VF
26
Virtu Financial
New York
$11K +$10.5K +33,195 New
FLC
27
Fifth Lane Capital
Texas
$8K +$7.91K +25,000 New
BCM
28
Bluefin Capital Management
New York
$5K +$4.74K +14,975 New
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$5K +$4.78K +15,124 New
Jane Street
30
Jane Street
New York
$4K +$3.74K +11,818 New
TRCT
31
Tower Research Capital (TRC)
New York
$3K +$3.1K +9,792 New
AA
32
Ancora Advisors
Ohio
$2K +$1.58K +5,000 New
UBS Group
33
UBS Group
Switzerland
$1K +$727 +2,298 New

DMAQR Hedge Fund Activity: Q4 2021 in Review

33 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q4 2021, worth a combined $3.2M.

Buyers outnumbered sellers: 33 funds opened new DMAQR positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Mangrove Partners, opening a new position worth an estimated $474K.

  • 33 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $3.2M of Deep Medicine Acquisition Corp. Rights stock for Q4 2021.
  • 33 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q4 2021 and 0 closed out, a net change of +33 holders.
  • The largest Deep Medicine Acquisition Corp. Rights buyer in Q4 2021 was Mangrove Partners, an estimated $474K added.

Based on aggregated 13F filings for Q4 2021.